Webinar: The results are in! Now what? - webinar materials now available online

The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) presented the results in a webinar held on 12 December 2017. The webinar explored implications for the field, from the delamanid C213 trial and the STREAM trial to evaluate the shorter regimen for MDR-TB.

Participants includes:

Dr. Francesca Conradie, Wits University
Dr. Carole Diane Mitnick, Harvard Medical School
Marcus Low, Spotlight
Mandy Slutsker, ACTION

Moderator: Erica Lessem, TAG’s Deputy Executive Director – TB Programs

To review the thoughtful presentations on the implications of the results, as well as the insightful questions posed to the presenters, visit the TAG website, where you can find the recorded webinar, transcript, presentations, and handouts.

Source: Treatment Action Group

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By Treatment Action Group, ACTION, DR-TB STAT

Published: Dec. 25, 2017, 9:45 p.m.

Last updated: Dec. 25, 2017, 10:49 p.m.

Tags: Events

Print Share